Opinion of the Transparency Council – rivastigmine
At its meeting on 22 April 2025, the Transparency Council adopted opinion No. 69/2025 on the inclusion of medicinal products containing the active substance rivastigmine in the scope of indications for use or dosage, or method of administration other than those specified in the Summary of Product Characteristics, i.e. dementia with Lewy bodies